Form 4: Verve Therapeutics Director's Stock Options Converted in Eli Lilly Merger

A Verve Therapeutics director's stock options were cancelled and converted to cash and contingent value rights as part of the company's merger with Eli Lilly and Company.

Summary

• Sheila Mikhail, a Director of Verve Therapeutics, Inc., reported the disposition of stock options.
• The options were cancelled as part of an Agreement and Plan of Merger dated June 16, 2025, involving Verve Therapeutics, Eli Lilly and Company, and Ridgeway Acquisition Corporation.
• Stock options with exercise prices of $5.02, $5.73, and $8.98 were cancelled on July 25, 2025.
• At the merger's effective time, all outstanding stock options with an exercise price less than $10.50 per share (the "Cash Consideration") were automatically cancelled.
• Holders of these "Cash-Out Stock Options" received a cash payment equal to the product of (Cash Consideration exercise price) multiplied by the total number of shares subject to the option.
• Additionally, holders received one non-tradeable contingent value right (CVR) for each share subject to the cancelled option.

Sentiment

Score: 7

Explanation: The filing details a standard transaction related to a merger, where stock options were converted into cash and contingent value rights. This is a procedural update following a significant corporate event (merger), which is generally positive for shareholders of the acquired company.

Positives

• The cancellation of in-the-money stock options (exercise price less than $10.50) resulted in a cash payout for the holder.
• Holders also received non-tradeable contingent value rights (CVRs), providing potential future value based on specific milestones.

Negatives

• Stock options were cancelled, meaning the holder no longer has direct equity exposure or future upside potential from the options themselves, beyond the CVRs.
• The contingent value rights (CVRs) are non-tradeable, limiting liquidity for that portion of the consideration.

Future Outlook

The filing indicates the completion of a merger between Verve Therapeutics and Eli Lilly and Company, leading to the cancellation of certain stock options in exchange for cash and contingent value rights. This implies Verve Therapeutics will become an indirect wholly-owned subsidiary of Eli Lilly.

Industry Context

This transaction reflects the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger companies like Eli Lilly acquire smaller, innovative firms like Verve Therapeutics to expand their pipelines and technological capabilities, often involving structured payouts including contingent value rights.

Comparison to Industry Standards

• The use of contingent value rights (CVRs) in biotech mergers is a common mechanism to bridge valuation gaps and incentivize the achievement of future milestones, similar to deals such as Bristol Myers Squibb's acquisition of Celgene or Merck's acquisition of Acceleron Pharma, where CVRs were used to tie additional payments to regulatory approvals or sales targets.
• The cash consideration for in-the-money options is standard practice in M&A transactions, ensuring option holders receive value for their vested and unvested options based on the deal price.

Stakeholder Impact

• Shareholders (of Verve Therapeutics): The merger implies their shares would have been acquired for the Cash Consideration and CVRs, aligning with the option treatment.
• Option Holders (like Sheila Mikhail): Received cash for in-the-money options and CVRs, converting illiquid options into liquid assets (cash) and potential future value (CVRs).

Key Dates

Keywords

Verve Therapeutics, Eli Lilly, Merger, Acquisition, Stock Options, Form 4, Insider Transaction, Contingent Value Rights, CVR, Biotechnology, Pharmaceuticals